Effects of FDA drug approvals on a thoracic oncology program’s clinical trial enrollment in 2015.

e20662Background: The 6 FDA drug approvals for non-small cell lung cancer (NSCLC) in 2015 included 2 programmed cell death protein 1 (PD-1) inhibitors and a 3rd generation (gen) epidermal growth fa...